Description
In the rapidly evolving field of immunotherapy, checkpoint inhibitors have emerged as groundbreaking treatments in the fight against cancer. These therapies, which work by unmasking the immune system’s potential to recognize and eliminate cancerous cells, have reshaped the landscape of oncology. However, the effectiveness of checkpoint inhibitors can be influenced by various factors, one of the most significant being the presence of myeloid-derived suppressor cells (MDSCs). MDSCs are a heterogeneous group of immune cells that play a pivotal role in suppressing the immune response, particularly in the context of cancer. This book aims to provide a comprehensive exploration of the intricate relationship between checkpoint inhibitors and MDSCs, detailing their mechanisms of action, clinical relevance, and potential therapeutic strategies.
